H.R. 6832 · 117th Congress
To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
- Stage
- In committee
- Sponsor
- Michael Cloud
- Introduced
- 2022-02-25
- Latest action
- 2022-02-28 · Referred to the Subcommittee on Health.